Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-01
DOI
10.3389/fonc.2022.782730
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy
- (2021) Asanka R. Wijetunga et al. EJSO
- Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial
- (2021) Stefano Cascinu et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
- (2021) Masaru Fukahori et al. MEDICINE
- Dosimetric feasibility on hypofractionated intensity-modulated radiotherapy and simultaneous integrated boost for locally advanced unresectable pancreatic cancer with helical tomotherapy
- (2021) Feng Teng et al. Journal of Gastrointestinal Oncology
- Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020
- (2021) Haibo Qiu et al. Cancer Communications
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
- (2020) Philip A Philip et al. Lancet Gastroenterology & Hepatology
- Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach
- (2020) Eugene J. Koay et al. Practical Radiation Oncology
- Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study
- (2020) Suayib Yalcin et al. BMC CANCER
- Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies
- (2020) Joseph Abi Jaoude et al. CURRENT PROBLEMS IN CANCER
- Pancreatic cancer
- (2020) Jonathan D Mizrahi et al. LANCET
- Intensified Systemic Therapy and Stereotactic Ablative Radiotherapy Dose for Patients with Unresectable Pancreatic Adenocarcinoma
- (2020) Diego A.S. Toesca et al. RADIOTHERAPY AND ONCOLOGY
- ESTRO ACROP guidelines for target volume definition in pancreatic cancer
- (2020) Thomas B. Brunner et al. RADIOTHERAPY AND ONCOLOGY
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
- (2020) Volker Kunzmann et al. Lancet Gastroenterology & Hepatology
- Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design
- (2019) Xiaofei Zhu et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results
- (2019) Marsha Reyngold et al. Radiation Oncology
- Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection
- (2018) Georgios Gemenetzis et al. ANNALS OF SURGERY
- Locally advanced pancreatic cancer: An emerging entity
- (2018) Grainne M. O′Kane et al. CURRENT PROBLEMS IN CANCER
- Therapeutic developments in pancreatic cancer: current and future perspectives
- (2018) John P. Neoptolemos et al. Nature Reviews Gastroenterology & Hepatology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy
- (2017) Seung Yeun Chung et al. RADIOTHERAPY AND ONCOLOGY
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Edward P. Balaban et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
- (2016) Kazumasa Fujitani et al. LANCET ONCOLOGY
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
- (2013) Somnath Mukherjee et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-dose Helical Tomotherapy With Concurrent Full-dose Chemotherapy for Locally Advanced Pancreatic Cancer
- (2012) Jee Suk Chang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer
- (2011) Devin Schellenberg et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started